464 related articles for article (PubMed ID: 33262763)
21. Inducing vascular normalization: A promising strategy for immunotherapy.
Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
[TBL] [Abstract][Full Text] [Related]
22. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Fukumura D; Kloepper J; Amoozgar Z; Duda DG; Jain RK
Nat Rev Clin Oncol; 2018 May; 15(5):325-340. PubMed ID: 29508855
[TBL] [Abstract][Full Text] [Related]
23. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
24. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
Yang L; Li A; Lei Q; Zhang Y
J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
[TBL] [Abstract][Full Text] [Related]
25. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
Saleh R; Elkord E
Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
[TBL] [Abstract][Full Text] [Related]
26. Targeting cancer-related inflammation in the era of immunotherapy.
Nakamura K; Smyth MJ
Immunol Cell Biol; 2017 Apr; 95(4):325-332. PubMed ID: 27999432
[TBL] [Abstract][Full Text] [Related]
27. Application of nanotechnology in circumventing immunotolerance.
Ma Y; Shen Y; Zhu B; Li D; Liu J
Pharmazie; 2020 Oct; 75(10):470-477. PubMed ID: 33305719
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-Driven Immune Escape in the Tumor Microenvironment.
Vito A; El-Sayes N; Mossman K
Cells; 2020 Apr; 9(4):. PubMed ID: 32316260
[TBL] [Abstract][Full Text] [Related]
29. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.
Makkouk A; Weiner GJ
Cancer Res; 2015 Jan; 75(1):5-10. PubMed ID: 25524899
[TBL] [Abstract][Full Text] [Related]
30. Overcoming tumor-mediated immunosuppression.
Schlößer HA; Theurich S; Shimabukuro-Vornhagen A; Holtick U; Stippel DL; von Bergwelt-Baildon M
Immunotherapy; 2014; 6(9):973-88. PubMed ID: 25341119
[TBL] [Abstract][Full Text] [Related]
31. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.
Hatfield SM; Sitkovsky M
Curr Opin Pharmacol; 2016 Aug; 29():90-6. PubMed ID: 27429212
[TBL] [Abstract][Full Text] [Related]
32. Combining microenvironment normalization strategies to improve cancer immunotherapy.
Mpekris F; Voutouri C; Baish JW; Duda DG; Munn LL; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3728-3737. PubMed ID: 32015113
[TBL] [Abstract][Full Text] [Related]
33. Cold to Hot: Tumor Immunotherapy by Promoting Vascular Normalization Based on PDGFB Nanocomposites.
Ma S; Tian Z; Liu L; Zhu J; Wang J; Zhao S; Zhu Y; Zhu J; Wang W; Jiang R; Qu Y; Lei J; Zhao J; Jiang T
Small; 2024 Apr; 20(16):e2308638. PubMed ID: 38018295
[TBL] [Abstract][Full Text] [Related]
34. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors.
Akbari P; Katsarou A; Daghighian R; van Mil LWHG; Huijbers EJM; Griffioen AW; van Beijnum JR
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188701. PubMed ID: 35202772
[TBL] [Abstract][Full Text] [Related]
35. Reprogramming endothelial cells to empower cancer immunotherapy.
Cleveland AH; Fan Y
Trends Mol Med; 2024 Feb; 30(2):126-135. PubMed ID: 38040601
[TBL] [Abstract][Full Text] [Related]
36. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
37. NK Cell Metabolism and Tumor Microenvironment.
Terrén I; Orrantia A; Vitallé J; Zenarruzabeitia O; Borrego F
Front Immunol; 2019; 10():2278. PubMed ID: 31616440
[TBL] [Abstract][Full Text] [Related]
38. Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.
Bule P; Aguiar SI; Aires-Da-Silva F; Dias JNR
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575965
[TBL] [Abstract][Full Text] [Related]
39. Cancer immunotherapy: the art of targeting the tumor immune microenvironment.
da Silva JL; Dos Santos ALS; Nunes NCC; de Moraes Lino da Silva F; Ferreira CGM; de Melo AC
Cancer Chemother Pharmacol; 2019 Aug; 84(2):227-240. PubMed ID: 31240384
[TBL] [Abstract][Full Text] [Related]
40. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
